BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
CLSA maintains outperform on Dr. Reddys Laboratories
US Approvals in the second half of this year to drive operating leverage. Next two quarters to provide direction for FY2018 earnings. DRL has completed all the remedial activities.